相关实验视频
Updated: Jan 12, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
895
患者使用利拉格卢提德治疗肥胖和暴饮暴食的经验 - - 一项定性研究
Ingrid Sørdal Følling1,2, Stine Larsen Reigstad1, Åsne Ask Hyldmo1,2
1Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
PloS one
|October 31, 2025
概括
患有肥胖和过度饮食障碍 (BED) 的患者发现,利拉格卢提德有效地管理情绪和身体需求,减少对食物的关注,并减少过度饮食的触发因素. 这种药物改善了他们的整体生活质量.
科学领域:
- 内分泌学 在内分泌学.
- 精神病学是一个精神病学.
- 行为科学 行为科学
背景情况:
- 肥胖是一个重要的健康问题,也是暴饮暴食障碍 (BED) 的危险因素.
- 药物,包括GLP-1类比的利拉格卢提德,可以帮助管理BED症状,并通过准奖励途径来支持减肥.
- 关于利拉格卢提德对肥胖和BED患者的影响的研究有限.
研究的目的:
- 质量地探索患者对利拉格卢提德治疗肥胖和BED的经验.
- 了解利拉格卢提德如何影响BED症状的表达和管理.
主要方法:
- 使用个人,半结构化,深度访谈进行定性研究设计.
- 采访了8名年龄在25-60岁的参与者.
- 在数据分析中使用了系统的文本缩写.
主要成果:
- 主题1:食物在BED表达中的作用 (情绪调节,饮食/节食想法,触发因素).
- 主题2:在管理BED (满足需求,减少食物想法,减少触发因素) 中使用利拉格卢提德的经验.
- 据报道,利拉格卢提德对BED症状的影响,影响了食物在BED表达中的作用.
结论:
- 利拉格卢提德似乎对肥胖和BED患者有益,帮助情绪/身体需求并提高幸福感.
- 他们注意到对社会互动和生活质量的积极影响.
- 需要进一步的研究来评估对情绪和行为变化的长期影响.
相关概念视频
Binge Eating Disorders
407
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
407
Bulimia Nervosa
662
Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
662
Glucagon-like Receptor Agonists
832
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
832
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Anorexia Nervosa
922
Anorexia nervosa is a complex and severe eating disorder characterized by an intense fear of weight gain, an unrelenting pursuit of thinness, and a distorted body image. It often leads to dangerously low body weight relative to an individual's age and height. This disorder is marked by significant physical and psychological consequences, making it one of the most life-threatening psychiatric illnesses.
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
922
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
233
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
233

